CR20250130A - Anticuerpos anti-lair1 humano - Google Patents

Anticuerpos anti-lair1 humano

Info

Publication number
CR20250130A
CR20250130A CR20250130A CR20250130A CR20250130A CR 20250130 A CR20250130 A CR 20250130A CR 20250130 A CR20250130 A CR 20250130A CR 20250130 A CR20250130 A CR 20250130A CR 20250130 A CR20250130 A CR 20250130A
Authority
CR
Costa Rica
Prior art keywords
antibodies
human lair1
human
lair1 antibodies
lair1
Prior art date
Application number
CR20250130A
Other languages
English (en)
Inventor
Monica Macal
Wei Wang
Reid Martin Renny Feldman
Andrew Charles Vendel
Julian Davies
Scott Charles Potter
Ramirez Maria Elena Ayala
Shireen Syrah Khan
Original Assignee
Lilly Co Eli
Trex Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, Trex Bio Inc filed Critical Lilly Co Eli
Publication of CR20250130A publication Critical patent/CR20250130A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Transplantation (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente descripción se relaciona con anticuerpos que se unen a LAIR1 humano (“anticuerpos anti-LAIR1 humano” o “anticuerpos anti-LAIR1 humano”), composiciones que comprenden dichos anticuerpos anti-LAIR1 humano y métodos para usar dichos anticuerpos anti-LAIR1 humano
CR20250130A 2022-09-16 2023-09-15 Anticuerpos anti-lair1 humano CR20250130A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263375936P 2022-09-16 2022-09-16
PCT/US2023/074294 WO2024059789A2 (en) 2022-09-16 2023-09-15 Anti-human lair1 antibodies

Publications (1)

Publication Number Publication Date
CR20250130A true CR20250130A (es) 2025-07-01

Family

ID=90275943

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20250130A CR20250130A (es) 2022-09-16 2023-09-15 Anticuerpos anti-lair1 humano

Country Status (18)

Country Link
US (1) US20240101670A1 (es)
EP (1) EP4587475A2 (es)
JP (1) JP2025532639A (es)
KR (1) KR20250080868A (es)
CN (1) CN120202223A (es)
AR (1) AR130506A1 (es)
AU (1) AU2023342134A1 (es)
CA (1) CA3267700A1 (es)
CL (1) CL2025000695A1 (es)
CO (1) CO2025003205A2 (es)
CR (1) CR20250130A (es)
DO (1) DOP2025000059A (es)
IL (1) IL319594A (es)
JO (1) JOP20250059A1 (es)
MX (1) MX2025003065A (es)
PE (1) PE20251693A1 (es)
TW (1) TW202426500A (es)
WO (1) WO2024059789A2 (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018204986B2 (en) * 2017-01-02 2024-08-01 The Board Of Regents Of The University Of Texas System Anti-LAIR1 antibodies and their uses
EP4168451A2 (en) * 2020-06-22 2023-04-26 NGM Biopharmaceuticals, Inc. Lair-1-binding agents and methods of use thereof

Also Published As

Publication number Publication date
US20240101670A1 (en) 2024-03-28
CA3267700A1 (en) 2024-03-21
WO2024059789A2 (en) 2024-03-21
PE20251693A1 (es) 2025-07-02
CO2025003205A2 (es) 2025-06-06
KR20250080868A (ko) 2025-06-05
CL2025000695A1 (es) 2025-07-04
MX2025003065A (es) 2025-08-01
WO2024059789A3 (en) 2024-05-16
AR130506A1 (es) 2024-12-11
EP4587475A2 (en) 2025-07-23
AU2023342134A1 (en) 2025-04-03
CN120202223A (zh) 2025-06-24
JOP20250059A1 (ar) 2025-03-13
TW202426500A (zh) 2024-07-01
DOP2025000059A (es) 2025-06-30
IL319594A (en) 2025-05-01
JP2025532639A (ja) 2025-10-01

Similar Documents

Publication Publication Date Title
ZA202209119B (en) Anti-human cd19 antibodies
MX2020013324A (es) Anticuerpos anti proteína reguladora de señales beta 1 (sirp-beta1) y métodos de uso de los mismos.
MY205789A (en) Anti-gdf15 antibodies, compositions and methods of use
ZA202211057B (en) Anti-trem2 antibodies and methods of use thereof
PH12020551930A1 (en) Anti-sirpa antibodies and methods of use thereof
ZA202206437B (en) Claudin18.2 binding moieties and uses thereof
PH12021550041A1 (en) Anti-sortilin antibodies and methods of use thereof
MX2022007231A (es) Anticuerpos anti-mertk y metodos de uso de los mismos.
WO2021022083A3 (en) Anti-ms4a4a antibodies and methods of use thereof
ZA202309516B (en) Anti-ccr8 antibodies
WO2021203030A3 (en) Methods of use of anti-trem2 antibodies
WO2022226342A3 (en) Modified anti-tslp antibodies
CR20210155A (es) Anticuerpos anti-cd33 y métodos para usarlos
WO2022040088A3 (en) Cd45 binding molecules and methods of use
MX2021000933A (es) Anticuerpos anti-siglec-5 y métodos para su uso.
WO2021262597A3 (en) Lair-1-binding agents and methods of use thereof
MX2025000790A (es) Anticuerpos anti-gpnmb y metodos de uso de estos
MX2024001644A (es) Anticuerpos contra el receptor alfa de la interleucina-4 humana.
MX2025005092A (es) Anticuerpo anti-trem2 y usos del mismo
ZA202305329B (en) Multi-specific antibodies and antibody combinations
MX2022009130A (es) Anticuerpos anti-e-selectina, composiciones y metodos de uso.
WO2021195385A8 (en) HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2)
MX2024005683A (es) Anticuerpos contra el factor de necrosis tumoral alfa humano.
MX2023012300A (es) Anticuerpos humanos contra artemina y metodos de uso de estos.
JOP20240054A1 (ar) الأجسام المضادة لناقل أحادي كربوكسيلات بشري 1 واستخداماتها